**8. References**


Contrast Medium-Induced Nephropathy (CIN)

0009-7322 (Linking)

ISSN 0002-9149 (Print)

ISSN 1076-6332 (Print)

ISSN 0938-7994 (Print)

(Electronic)

Gram-Iodine/GFR Ratio to Predict CIN and Strategies to Reduce Contrast Medium Doses 207

Davidson CJ, Stacul F, McCullough PA, Tumlin J, Adam A, Lameire N, Becker CR (2006).

DuBois D, DuBois E (1916). A formula to estimate the approximate surface area if height and

Duncan L, Heathcote J, Djurdjev O, Levin A (2001). Screening for renal disease using serum

Elmståhl B, Nyman U, Leander P, Chai CM, Frennby B, Almén T (2004). Gadolinium

Elmståhl B, Nyman U, Leander P, Golman K, Chai CM, Grant D, Doughty R, Pehrson R,

Ergun I, Keven K, Uruc I, Ekmekci Y, Canbakan B, Erden I, Karatan O (2006). The safety of

Fleischmann D (2003). Use of high-concentration contrast media in multiple-detector-row

Flinck M, Graden A, Milde H, Flinck A, Hellstrom M, Bjork J, Nyman U (2010). Cardiac

Freeman RV, O'Donnell M, Share D, Meengs WL, Kline-Rogers E, Clark VL, DeFranco AC,

Frennby B, Sterner G (2002). Contrast media as markers of GFR. *Eur Radiol,* Vol.12, No.2,

From AM, Al Badarin FJ, McDonald FS, Bartholmai BJ, Cha SS, Rihal CS (2010). Iodixanol

Vol.3, No.4 pp. 351-358, ISSN 1941-7632 (Electronic), 1941-7640 (Linking) From AM, Bartholmai BJ, Williams AW, Cha SS, McDonald FS (2008). Mortality associated

Garcia-Ruiz C, Martinez-Vea A, Sempere T, Sauri A, Olona M, Peralta C, Oliver A (2004).

No.10, (2008 Oct), pp. 1095-1100, ISSN 1942-5546 (Electronic)

Vol.21, No.3, (2006 Mar), pp. 697-700, ISSN 0931-0509 (Print)

ISSN 1600-0455 (Electronic), 0284-1851 (Linking)

ISSN 0002-9149 (Print), 0002-9149 (Linking)

(2002 Feb), pp. 475-484, ISSN 0938-7994 (Print)

weight be known. *Arch Intern Med,* Vol.17, pp. 863-871

pp. 1042-1046, ISSN 0931-0509 (Print)

(2000). Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. *Circulation,* Vol.101, No.18 pp. 2172-2177, ISSN 1524-4539 (Electronic),

Contrast medium use. *Am J Cardiol,* Vol.98, No.6A, (2006 Sep 18), pp. 42K-58K,

creatinine: who are we missing? *Nephrol Dial Transplant,* Vol.16, No.5, (2001 May),

contrast media are more nephrotoxic than a low osmolar iodine medium employing doses with equal X-ray attenuation in renal arteriography: an experimental study in pigs. *Acad Radiol,* Vol.11, No.11, (2004 Nov), pp. 1219-1228,

Bjork J, Almen T (2008). Iodixanol 320 results in better renal tolerance and radiodensity than do gadolinium-based contrast media: arteriography in ischemic porcine kidneys. *Radiology,* Vol.247, No.1, (2008 Apr), pp. 88-97, ISSN 1527-1315

gadolinium in patients with stage 3 and 4 renal failure. *Nephrol Dial Transplant,*

CT: principles and rationale. *Eur Radiol,* Vol.13 Suppl 5, (2003 Dec), pp. M14-20,

output measured by electrical velocimetry in the CT suite correlates with coronary artery enhancement: a feasibility study. *Acta Radiol,* Vol.51, No.8, (Oct), pp. 895-902,

Eagle KA, McGinnity JG, Patel K, Maxwell-Eward A, Bondie D, Moscucci M (2002). Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. *Am J Cardiol,* Vol.90, No.10 pp. 1068-1073,

versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials. *Circ Cardiovasc Interv,*

with nephropathy after radiographic contrast exposure. *Mayo Clin Proc,* Vol.83,

Low risk of contrast nephropathy in high-risk patients undergoing spiral computed


Bae KT, Mody GN, Balfe DM, Bhalla S, Gierada DS, Gutierrez FR, Menias CO, Woodard PK,

Barrett BJ, Carlisle EJ (1993). Metaanalysis of the relative nephrotoxicity of high- and low-

Barrett BJ, Katzberg RW, Thomsen HS, Chen N, Sahani D, Soulez G, Heiken JP, Lepanto L,

Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, Grines CL,

Becker CR, Reiser MF (2005). Use of iso-osmolar nonionic dimeric contrast media in

Biondi-Zoccai GG, Lotrionte M, Abbate A, Testa L, Remigi E, Burzotta F, Valgimigli M,

(Jan 28), pp. 202-209, ISSN 1468-5833 (Electronic), 0959-535X (Linking) Briguori C, Colombo A, Airoldi F, Melzi G, Michev I, Carlino M, Montorfano M, Chieffo A,

145, ISSN 0910-8327 (Print)

178, ISSN 0033-8419 (Print)

Jun 15), pp. 1515-1519, ISSN 0002-9149 (Print)

0020-9996 (Print)

(Print)

8703 (Linking)

Goo JM, Hildebolt CF (2005). CT depiction of pulmonary emboli: display window settings. *Radiology,* Vol.236, No.2, (2005 Aug), pp. 677-684, ISSN 0033-8419 (Print) Barcin C, Kursaklioglu H, Iyisoy A, Kose S, Tore HF, Isik E (2006). Safety of gadodiamide

mixed with a small quantity of iohexol in patients with impaired renal function undergoing coronary angiography. *Heart Vessels,* Vol.21, No.3, (2006 May), pp. 141-

osmolality iodinated contrast media. *Radiology,* Vol.188, No.1, (1993 Jul), pp. 171-

Ni ZH, Nelson R (2006). Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. *Invest Radiol,* Vol.41, No.11, (2006 Nov), pp. 815-821, ISSN

O'Neill WW (2004). Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. *Am J Cardiol,* Vol.93, No.12, (2004

multidetector row computed tomography angiography for patients with renal impairment. *Invest Radiol,* Vol.40, No.10, (2005 Oct), pp. 672-675, ISSN 0020-9996

Romagnoli E, Crea F, Agostoni P (2006). Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. *BMJ,* Vol.332, No.7535,

Bellanca R, Ricciardelli B (2006). Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. *Catheter Cardiovasc Interv,* Vol.67, No.2, (2006 Feb), pp. 175-180, ISSN 1522-1946 (Print) Brown JR, DeVries JT, Piper WD, Robb JF, Hearne MJ, Ver Lee PM, Kellet MA, Watkins

MW, Ryan TJ, Silver MT, Ross CS, MacKenzie TA, O'Connor GT, Malenka DJ (2008). Serious renal dysfunction after percutaneous coronary interventions can be predicted. *Am Heart J,* Vol.155, No.2 pp. 260-266, ISSN 1097-6744 (Electronic), 0002-

Buhaescu I, Izzedine H (2008). Gadolinium-induced nephrotoxicity. *Int J Clin Pract,* Vol.62, No.7, (2008 Jul), pp. 1113-1118, ISSN 1742-1241 (Electronic), 1368-5031 (Linking) Chen M-L, Lekso L, Williams R (2001). Measures of exposure versus measures of rate and

Cigarroa RG, Lange RA, Williams RH, Hillis LD (1989). Dosing of contrast material to

Davidson CJ, Laskey WK, Hermiller JB, Harrison JK, Matthai W, Jr., Vlietstra RE, Brinker JA,

prevent contrast nephropathy in patients with renal disease. *Am J Med,* Vol.86, No.6

Kereiakes DJ, Muhlestein JB, Lansky A, Popma JJ, Buchbinder M, Hirshfeld JW, Jr.

extent of absorption. *Clin Pharmacokinet,* Vol.40, pp. 565-572

Pt 1, (1989 Jun), pp. 649-652, ISSN 0002-9343 (Print)

(2000). Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. *Circulation,* Vol.101, No.18 pp. 2172-2177, ISSN 1524-4539 (Electronic), 0009-7322 (Linking)


Contrast Medium-Induced Nephropathy (CIN)

3597 (Electronic)

Gram-Iodine/GFR Ratio to Predict CIN and Strategies to Reduce Contrast Medium Doses 209

Kristiansson M, Holmquist F, Nyman U (2010). Ultralow contrast medium doses at CT to

Laskey WK, Jenkins C, Selzer F, Marroquin OC, Wilensky RL, Glaser R, Cohen HA, Holmes

Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F (2007).

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW,

Liu Y, Tan N, Zhou YL, He PC, Luo JF, Chen JY (2011). The contrast medium volume to

Lufft V, Hoogestraat-Lufft L, Fels LM, Egbeyong-Baiyee D, Tusch G, Galanski M, Olbricht

Mager A, Assa HV, Lev EI, Bental T, Assali A, Kornowski R (2010). The ratio of contrast

Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, Moltrasio M,

Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, Grazi M, Veglia F,

McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, Tumlin J (2006a).

*Cardiol,* Vol.98, No.6A, (2006 Sep 18), pp. 5K-13K, ISSN 0002-9149 (Print)

impairment. A feasibility study. *Eur Radiol,* Vol.20, No.6, pp. 1321-1330 Kuhn MJ, Chen N, Sahani DV, Reimer D, van Beek EJ, Heiken JP, So GJ (2008). The

Vol.191, No.1, (2008 Jul), pp. 151-157, ISSN 1546-3141 (Electronic)

Vol.53, No.4, (2007 Apr), pp. 766-772, ISSN 0009-9147 (Print)

ISSN 1539-3704 (Electronic), 1539-3704 (Linking)

2584 (Electronic), 0301-1623 (Linking)

(Electronic), 0272-6386 (Linking)

726X (Electronic), 1522-1946 (Linking)

ISSN 1539-3704 (Electronic), 0003-4819 (Linking)

(2004 Nov 2), pp. 1780-1785, ISSN 0735-1097 (Print)

diagnose pulmonary embolism in patients with moderate to severe renal

PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. *AJR Am J Roentgenol,*

DR, Jr. (2007). Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. *J Am Coll Cardiol,* Vol.50, No.7, (2007 Aug 14), pp. 584-590, ISSN 1558-

Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. *Clin Chem,*

Eggers P, Van Lente F, Greene T, Coresh J (2009). A new equation to estimate glomerular filtration rate. *Ann Intern Med,* Vol.150, No.9, (2009 May 5), pp. 604-612,

estimated glomerular filtration rate ratio as a predictor of contrast-induced nephropathy after primary percutaneous coronary intervention. *Int Urol Nephrol*, (Feb 20), Epub ahead of print, doi:10.1007/s11255-11011-19910-11254, ISSN 1573-

CJ (2002). Contrast media nephropathy: intravenous CT angiography versus intraarterial digital subtraction angiography in renal artery stenosis: a prospective randomized trial. *Am J Kidney Dis,* Vol.40, No.2, (Aug), pp. 236-242, ISSN 1523-6838

volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction. *Catheter Cardiovasc Interv*, (Oct 14), Epub ahead of print, doi: 10.1002/ccd.22828, ISSN 1522-

Grazi M, Rubino M, Veglia F, Fabbiocchi F, Bartorelli AL (2009). Contrast volume during primary percutaneous coronary intervention and subsequent contrastinduced nephropathy and mortality. *Ann Intern Med,* Vol.150, No.3 pp. 170-177,

Bartorelli AL (2004). Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol,* Vol.44, No.9,

Epidemiology and prognostic implications of contrast-induced nephropathy. *Am J* 

tomography angiography with the contrast medium iopromide and prophylactic oral hydratation. *Clin Nephrol,* Vol.61, No.3, (Mar), pp. 170-176, ISSN 0301-0430 (Print), 0301-0430 (Linking)


doi: 10.1016/j.jvir.2011.03.020, ISSN 1535-7732 (Electronic), 1051-0443 (Linking)


Gupta R, Uretsky BF (2005). Gadodiamide-based coronary angiography in a patient with

Gurm HS, Dixon SR, Smith DE, Share D, LaLonde T, Greenbaum A, Moscucci M (2011).

Holmquist F, Hansson K, Pasquariello F, Bjork J, Nyman U (2009). Minimizing Contrast

Holmquist F, Nyman U (2006). Eighty-peak kilovoltage 16-channel multidetector computed

Johnson PT, Naidich D, Fishman EK (2007). MDCT for suspected pulmonary embolism:

Kakkar R, Sobieszczyk P, Binkert CA, Faxon DP, Mortele KJ, Singh AK (2008). Prevention of

Kane GC, Doyle BJ, Lerman A, Barsness GW, Best PJ, Rihal CS (2008). Ultra-low contrast

(2008 Jan 1), pp. 89-90, ISSN 1558-3597 (Electronic), 0735-1097 (Linking) Karlsberg RP, Dohad SY, Sheng R (2011). Contrast Medium-induced Acute Kidney Injury:

(Print), 0301-0430 (Linking)

*Cardiol,* Vol.58, pp. 907-914.

181-193, ISSN 1600-0455 (Electronic)

(2006 May), pp. 1165-1176, ISSN 0938-7994 (Print)

Vol.13, No.5, (2007 Feb), pp. 243-249, ISSN 1070-3004 (Print)

Medium. *J Vasc Interv Radiol*, pp. 1-7, Epub ahead of print,

ISSN 0896-4327 (Print)

0033-8419 (Print)

*Radiol,* Vol.13, pp. B32-B33

tomography angiography with the contrast medium iopromide and prophylactic oral hydratation. *Clin Nephrol,* Vol.61, No.3, (Mar), pp. 170-176, ISSN 0301-0430

severe renal insufficiency. *J Interv Cardiol,* Vol.18, No.5, (2005 Oct), pp. 379-383,

Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. *J Am Coll* 

Medium Doses to Diagnose Pulmonary Embolism with 80-kVp Multidetector Computed Tomography in Azotemic Patients. *Acta Radiol,* Vol.50, (2009 Jan 23), pp.

tomography and reduced contrast-medium doses tailored to body weight to diagnose pulmonary embolism in azotaemic patients. *Eur Radiol,* Vol.16, No.5,

multi-institutional survey of 16-MDCT data acquisition protocols. *Emerg Radiol,*

intravenous contrast-induced nephropathy in hospital inpatients. *Crit Pathw Cardiol,* Vol.7, No.1, (Mar), pp. 1-4, ISSN 1535-2811 (Electronic), 1535-2811 (Linking)

volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. *J Am Coll Cardiol,* Vol.51, No.1,

Comparison of Intravenous and Intraarterial Administration of Iodinated Contrast

with intravenous administration. *Radiology,* Vol.243, No.3, (2007 Jun), pp. 622-628,

is the medical risk really as great as we have come to believe? *Radiology,* Vol.256,

effectiveness of drugs for preventing contrast-induced nephropathy. *Ann Intern* 

with renal failure (P27). 10th European Symposium on Urogenital Radiology. *Euro* 

of the upper abdomen: effect of contrast medium and body weight. *Invest Radiol,*

doi: 10.1016/j.jvir.2011.03.020, ISSN 1535-7732 (Electronic), 1051-0443 (Linking) Katzberg RW, Barrett BJ (2007). Risk of iodinated contrast material--induced nephropathy

Katzberg RW, Newhouse JH (2010). Intravenous contrast medium-induced nephrotoxicity:

*Med,* Vol.148, No.4, (2008 Feb 19), pp. 284-294, ISSN 1539-3704 (Electronic) Kolehemainen H, Sovia M (2003). Comparison of Xenetix 300 and Visipaque 320 in patients

Kormano M, Partanen K, Soimakallio S, Kivimaki T (1983). Dynamic contrast enhancement

Vol.18, No.4, (1983 Jul-Aug), pp. 364-367, ISSN 0020-9996 (Print)

No.1, (Jul), pp. 21-28, ISSN 1527-1315 (Electronic), 0033-8419 (Linking) Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC (2008). Meta-analysis:


Contrast Medium-Induced Nephropathy (CIN)

ISSN 0009-9147 (Print)

116481-6, Stuttgart

0735-1097 (Linking)

0033-8389 (Linking)

(Print)

Gram-Iodine/GFR Ratio to Predict CIN and Strategies to Reduce Contrast Medium Doses 211

Nyman U, Elmståhl B, Leander P, Nilsson M, Golman K, Almén T (2002). Are gadolinium-

Perrone RD, Madias NE, Levey AS (1992). Serum creatinine as an index of renal function:

Polena S, Yang S, Alam R, Gricius J, Gupta JR, Badalova N, Chuang P, Gintautas J, Conetta R

Prokop M (2003). Image analysis In: *Spiral and multislice computed tomography of the body.* 

Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008). Cardiorenal syndrome. *J Am* 

Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, Hill JA,

Sam AD, 2nd, Morasch MD, Collins J, Song G, Chen R, Pereles FS (2003). Safety of

*Vasc Surg,* Vol.38, No.2, (2003 Aug), pp. 313-318, ISSN 0741-5214 (Print) Sarkis A, Badaoui G, Azar R, Sleilaty G, Bassil R, Jebara VA (2003). Gadolinium-enhanced

Vol.91, No.8, (2003 Apr 15), pp. 974-975, A974, ISSN 0002-9149 (Print) Sherwin PF, Cambron R, Johnson JA, Pierro JA (2005). Contrast dose-to-creatinine clearance

Spinosa DJ, Angle JF, Hartwell GD, Hagspiel KD, Leung DA, Matsumoto AH (2002).

Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA, Tumlin J (2006).

Sterner G, Nyman U, Valdes T (2001). Low risk of contrast-medium-induced nephropathy

Stevens LA, Coresh J, Greene T, Levey AS (2006). Assessing kidney function--measured and

No.6A, (2006 Sep 18), pp. 59K-77K, ISSN 0002-9149 (Print)

429-434, ISSN 0954-6820 (Print), 0954-6820 (Linking)

2473-2483, ISSN 1533-4406 (Electronic)

*West Pharmacol Soc,* Vol.48, (2005), pp. 134-135, ISSN 0083-8969 (Print) Prince MR, Arnoldus C, Frisoli JK (1996). Nephrotoxicity of high-dose gadolinium

Feb), pp. 162-166, ISSN 1053-1807 (Print), 1053-1807 (Linking)

311-318; discussion 328-319, ISSN 0033-8419 (Print)

based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia? *Radiology,* Vol.223, No.2, (2002 May), pp.

new insights into old concepts. *Clin Chem,* Vol.38, No.10, (1992 Oct), pp. 1933-1953,

(2005). Nephropathy in critically Ill patients without preexisting renal disease. *Proc* 

compared with iodinated contrast. *J Magn Reson Imaging,* Vol.6, No.1, (1996 Jan-

Prokop M, Galanski M, Van der Molen AJ, Schaefer-Prokop C, Thieme, ISBN 3-13-

*Coll Cardiol,* Vol.52, No.19, (Nov 4), pp. 1527-1539, ISSN 1558-3597 (Electronic),

Winniford M, Cohen MB, VanFossen DB (1995). Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. *Kidney Int,* Vol.47, No.1, (1995 Jan), pp. 254-261, ISSN 0085-2538

gadolinium contrast angiography in patients with chronic renal insufficiency. *J* 

coronary angiography in patients with impaired renal function. *Am J Cardiol,*

ratio as a potential indicator of risk for radiocontrast-induced nephropathy: correlation of D/CrCL with area under the contrast concentration-time curve using iodixanol. *Invest Radiol,* Vol.40, No.9, (2005 Sep), pp. 598-603, ISSN 0020-9996 (Print)

Gadolinium-based contrast agents in angiography and interventional radiology. *Radiol Clin North Am,* Vol.40, No.4, (2002 Jul), pp. 693-710, ISSN 0033-8389 (Print),

Strategies to reduce the risk of contrast-induced nephropathy. *Am J Cardiol,* Vol.98,

with modern angiographic technique. *J Intern Med,* Vol.250, No.5, (2001 Nov), pp.

estimated glomerular filtration rate. *N Engl J Med,* Vol.354, No.23, (2006 Jun 8), pp.


McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, Tumlin J (2006b).

Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ,

Mehran R, Nikolsky E (2006). Contrast-induced nephropathy: definition, epidemiology, and

Mitchell AM, Jones AE, Tumlin JA, Kline JA (2010). Incidence of contrast-induced

Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, Hostetter T, Levey AS,

Nash K, Hafeez A, Hou S (2002). Hospital-acquired renal insufficiency. *Am J Kidney Dis,*

Nguyen SA, Suranyi P, Ravenel JG, Randall PK, Romano PB, Strom KA, Costello P, Schoepf

Nozue T, Michishita I, Iwaki T, Mizuguchi I, Miura M (2009). Contrast medium volume to

Nyman U, Almen T, Aspelin P, Hellström M, Kristiansson M, Sterner G (2005). Contrast-

Nyman U, Björk J, Aspelin P, Marenzi G (2008). Contrast medium dose-to-GFR ratio: A

percutaneous coronary intervention. *Acta Radiol* Vol.49, pp. 658-667, Nyman U, Björk J, Sterner G, Bäck SE, Carlson J, Lindström V, Bakoush O, Grubb A (2006).

*Clin Lab Invest,* Vol.66, No.6, (2006), pp. 451-468, ISSN 0036-5513 (Print) Nyman U, Elmstahl B, Geijer H, Leander P, Almen T, Nilsson M (2011). Iodine contrast iso-

Vol.39, No.5, (2002 May), pp. 930-936, ISSN 1523-6838 (Electronic)

No.1, (2008 Jul), pp. 97-105, ISSN 1527-1315 (Electronic)

Sep 18), pp. 27K-36K, ISSN 0002-9149 (Print)

1393- ISSN 1399, 0735-1097 (Print)

pp. 5-18, ISSN 0009-9147 (Print)

6577 (Print)

(Linking)

ISSN 0284-1851 (Print)

1555-9041 (Linking)

Risk prediction of contrast-induced nephropathy. *Am J Cardiol,* Vol.98, No.6A, (2006

Moses JW, Stone GW, Leon MB, Dangas G (2004). A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol,* Vol.44, No.7, (2004 Oct 6), pp.

patients at risk. *Kidney Int Suppl,* Vol.69, No.100, (2006 Apr), pp. S11-15, ISSN 0098-

nephropathy after contrast-enhanced computed tomography in the outpatient setting. *Clin J Am Soc Nephrol,* Vol.5, No.1 pp. 4-9, ISSN 1555-905X (Electronic),

Panteghini M, Welch M, Eckfeldt JH (2006). Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. *Clin Chem,* Vol.52, No.1, (2006 Jan),

UJ (2008). Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function. *Radiology,* Vol.248,

estimated glomerular filtration rate ratio as a predictor of contrast-induced nephropathy developing after elective percutaneous coronary intervention. *J Cardiol,* Vol.54, No.2, (Oct), pp. 214-220, ISSN 1876-4738 (Electronic), 0914-5087

medium-Induced nephropathy correlated to the ratio between dose in gram iodine and estimated GFR in ml/min. *Acta Radiol,* Vol.46, No.8, (2005 Dec), pp. 830-842,

measure of systemic exposure to predict contrast-induced nephropathy after

Standardization of p-creatinine assays and use of lean body mass allow improved prediction of calculated glomerular filtration rate in adults: a new equation. *Scand J* 

attenuating with diagnostic gadolinium doses in CTA and angiography results in ultra-low iodine doses. A way to avoid both CIN and NSF in azotemic patients? *Eur Radiol,* Vol.21, (Aug 29), pp. 326-336, ISSN 1432-1084 (Electronic), 0938-7994 (Linking)


**11** 

*USA* 

**Pharmacotherapy During** 

David C. Yang and Dmitriy N. Feldman

*Weill Cornell Medical College, New York, NY* 

**Percutaneous Coronary Interventions** 

*Greenberg Division of Cardiology, New York Presbyterian Hospital,* 

Percutaneous arterial catheterization and transluminal dilatation of stenotic vessels were first described by Charles T. Dotter and Melvin P. Judkins in their seminal paper published in 1964 (1). With the advent of contemporary coronary angioplasty and stenting techniques for patients with coronary artery disease (CAD) and acute coronary syndromes (ACS), the procedure has now been termed percutaneous coronary intervention (PCI). While PCI has done much in the modern era to improve patient outcomes in the face of acute myocardial infarction as well as in disabling cardiac angina, its benefits can still be limited by periprocedural complications such as acute vessel closure and stent thrombosis as well as conditions occurring after 30 days post-PCI, such as in-stent restenosis or late stent thrombosis. Additionally, catheter and wire associated thrombus formation can occur during PCI in the absence of adequate anticoagulation. Excess anticoagulation on the other hand carries a risk of major gastrointestinal or intracranial bleeding as well as vascular access bleeding complications. Stent thrombosis is a rare, but serious complication of PCI and usually presents as death or ST-elevation myocardial infarction. Coronary stents are generally made of stainless steel or cobalt chromium alloys rendering them thrombogenic until they are completely covered by endothelial tissue. The timing of complete endothelialization is variable and depends on whether the implanted stent is bare metal or drug-eluting, as well as which type of anti-proliferative drug the stent is coated with. Stent thrombosis can be described based on its timing relative to stent placement and is associated with a number of different risk factors (Table 1). Acute stent thrombosis occurs within 24 hours of PCI and in one pooled analysis, approximately 80 percent of all bare metal stent (BMS) thromboses occurred within this acute period (2). Subacute stent thrombosis occurs up to 30 days after PCI and this time period encompasses the majority of all thrombotic events observed in both BMS and drug-eluting stents (DES) (3). Stent thrombosis after 30 days and up to one year post-PCI is referred to as late stent thrombosis and seems to occur with equal frequency in BMS and DES, particularly in the absence or cessation of dual antiplatelet therapy with aspirin or clopidogrel (4-5). Occurring even less commonly at greater than one year post-PCI, very late stent thrombosis appears to be associated with DES more than BMS and is thought to be related to delayed neo-intimal coverage as well as ongoing vessel inflammation (6). Current ACC/AHA guidelines make a number of recommendations regarding the concurrent use of antiplatelet, antithrombotic, and

**1. Introduction** 

